EU H2020 Project "PANAMAST (Progressing a non-antibiotic antimicrobial treatment for Bovine Mastitis..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/211127/index.html

PanaMast project word cloud

Explore the words cloud of the PanaMast project. It provides you a very rough idea of what is the project "PanaMast" about.

strategic industry roadmap antibiotic milk sites progress successfully regulatory innovation animal launch killing trl8 stage detailing resistance clinical underpin medicine mastitis farms quality farmers superior infectious sustainable 40bn solution world product urgently wwh reduce company dairy innovative ireland environmental rendering health global treatment wastage allowed food annually inducing westway sale galway ahead plan track solutions mrsa commercial commercialisation crisis ineffective economically cows budget 2020 assist veterinary herd market 150 antimicrobials treatments 30 culling panamasttm first supports performance resistant schedule profitability bacteria gains safe disease financial designed antibiotics relationships panamast markets trl7 breakthrough bovine lc outcomes

Project "PanaMast" data sheet

The following table provides information about the project.

Coordinator	SLAINTE BEOGA TEORANTA Organization address address: UNIT 204 BUSINESS INNOVATION CENTRE NUIG NEWCASTLE city: GALWAY postcode: H91 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	http://www.westwayhealth.com
Total cost	3˙549˙237 €
EC max contribution	2˙484˙466 € (70%)
Programme	1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy) 2. H2020-EU.3.2.1. (Sustainable agriculture and forestry) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-06-01 to 2019-05-31

#	participants	country	role	EC contrib. [€]
1	SLAINTE BEOGA TEORANTA	IE (GALWAY)	coordinator	2˙484˙466.00

SLAINTE BEOGA TEORANTA

IE (GALWAY)

coordinator

2˙484˙466.00

Project objective

The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LC The Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020

List of deliverables.
Project website	Websites, patent fillings, videos etc.	2019-04-18 14:42:25

Publications

List of publications.
year	authors and title	journal	last update
2018	Lilit Tonoyan, Aoife Boyd, Gerard T.A. Fleming, Ruairi Friel, Carol M. Gately, Paul H. Mc Cay, Vincent O\'Flaherty In vitro comparative cytotoxicity study of a novel biocidal iodo-thiocyanate complex published pages: 264-273, ISSN: 0887-2333, DOI: 10.1016/j.tiv.2018.03.014	Toxicology in Vitro 50	2019-06-11
2017	Lilit Tonoyan, Gerard T. A. Fleming, Paul H. Mc Cay, Ruairi Friel, Vincent O\'Flaherty Antibacterial Potential of an Antimicrobial Agent Inspired by Peroxidase-Catalyzed Systems published pages: , ISSN: 1664-302X, DOI: 10.3389/fmicb.2017.00680	Frontiers in Microbiology 8	2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANAMAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANAMAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)